Researchers at the Mayo Clinic have developed a risk calculator that can estimate a person’s likelihood of developing mild cognitive impairment or dementia up to 10 years before symptoms appear. The tool is based on a large analysis of data from the Mayo Clinic Study of Aging, which has followed thousands of adults for nearly two decades.
The study, published in The Lancet Neurology, evaluated nearly 5,900 cognitively healthy adults using four major predictors: age, sex, the APOE ε4 gene, and brain amyloid levels measured by PET scans. With those inputs, scientists estimated each person’s 10-year and lifetime risk of developing mild cognitive impairment or dementia. The researchers continued tracking participants even after they left the study, using medical records, which gave them unusually accurate insight into real-world Alzheimer’s risk.
Key findings
Three main insights emerged from the analysis. First, brain amyloid was the strongest predictor of future decline. Amyloid proteins begin accumulating silently in the brain decades before cognitive changes appear. People with higher amyloid levels had significantly greater 10-year and lifetime risk across all ages, sexes, and genetic backgrounds. Among 75-year-old carriers of the APOE ε4 gene, the lifetime risk of mild cognitive impairment jumped from 56% with low amyloid to over 80% with high amyloid.
Second, women carried a higher lifetime risk of mild cognitive impairment and dementia than men. This matches long-standing epidemiological patterns. The reasons include hormonal shifts, immune differences, and longer life expectancy.
Third, genetics still mattered. Carriers of the APOE ε4 gene had higher risk across all ages and amyloid levels. But amyloid amplified that genetic vulnerability, suggesting that genes and brain biology interact long before symptoms surface.
Implications for prevention
The study’s authors noted that the risk tool is still a research instrument, but it points toward a future where brain health is individualized, similar to how cholesterol and coronary calcium scores changed heart-disease prevention. They said Alzheimer’s care is moving toward a model where risk is identified long before memory changes occur, potentially guiding when someone should consider amyloid-lowering therapies or intensify lifestyle interventions.
The original article also listed daily habits that research has repeatedly linked to stronger cognition and slower decline. These include building cardiorespiratory fitness, supporting metabolic health, prioritizing high-quality sleep, eating a nutrient-rich diet, staying socially connected, and continuing to learn new things. The article also promoted a supplement called brain guard+.
The analysis appeared in The Lancet Neurology and was based on one of the most comprehensive brain-aging datasets available.
